Natalizumab
- Generic Name
- Natalizumab
- Brand Names
- Tysabri, Tyruko
- Drug Type
- Biotech
- CAS Number
- 189261-10-7
- Unique Ingredient Identifier
- 3JB47N2Q2P
- Background
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.
- Indication
Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate, conventional therapies and inhibitors of TNF-α. It is not to be used in combination with immunosuppressants or inhibitors of TNF-α.
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Severe Crohn's Disease, Moderate Crohn’s Disease
Royalty Pharma Secures 99.9% Shareholder Approval for $1.1 Billion External Manager Acquisition
• Royalty Pharma shareholders have overwhelmingly approved the acquisition of its external manager, with 99.9% voting in favor at the company's 2025 Annual General Meeting.
• The $1.1 billion transaction will transition Royalty Pharma from an external management model to an integrated corporate structure, generating projected cash savings exceeding $1.6 billion over ten years.
• The internalization is expected to strengthen corporate governance, enhance transparency, and better align leadership with shareholder interests while ensuring management continuity.
Phase 4 Trial Explores Ozanimod Switch for Stable MS Patients on Anti-CD20 Therapy
• A new Phase 4 study led by Dr. Enrique Alvarez will evaluate the safety and efficacy of transitioning stable multiple sclerosis patients from anti-CD20 therapy to oral ozanimod.
• The trial aims to enroll 500 patients who have shown no inflammatory disease activity for at least 2 years, with primary endpoints focusing on new T2 lesions and serious infection rates.
• The study addresses the growing interest in de-escalation strategies for MS treatment, offering potential advantages of ozanimod's once-daily oral administration and favorable safety profile.
FDA Approves Lilly's Omvoh (mirikizumab) for Crohn's Disease
• The FDA has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn's disease in adults, expanding its use for inflammatory bowel disease.
• The approval was based on the VIVID-1 trial, which showed significant clinical remission and endoscopic response rates compared to placebo after one year of treatment.
• Omvoh is the first biologic in over 15 years with Phase 3 two-year efficacy data at launch, demonstrating long-term disease control and visible healing of the intestinal lining.
• Lilly has submitted marketing applications globally, aiming to provide a new treatment option for Crohn's patients and is working with insurers to enable patient access.
FDA Clarifies Confirmatory Trial Requirements for Accelerated Drug Approvals
• The FDA issued draft guidance clarifying requirements for confirmatory trials needed to verify clinical benefit of drugs receiving accelerated approval.
• The guidance emphasizes early consultation with the FDA on trial design and the need for sponsors to commit sufficient resources for timely trial completion.
• The FDA intends to require confirmatory trials to be underway before granting accelerated approval, except in limited circumstances.
• The guidance also details procedures for expedited withdrawal of approval if confirmatory trials fail or other issues arise, ensuring accountability.
FDA Approves Steqeyma and Yesintek: Expanding Biosimilar Options for Stelara
• The FDA has approved Steqeyma (ustekinumab-stba) and Yesintek (ustekinumab-kfce) as biosimilars to Stelara, offering new options for patients with autoimmune and inflammatory conditions.
• Steqeyma and Yesintek are approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, mirroring Stelara's indications.
• These approvals are expected to increase market competition and reduce treatment costs, with launches anticipated in early 2025 following licensing agreements.
EMA Recommends Approval for Biogen's Leqembi with Patient Limitations
• The European Medicines Agency (EMA) has reversed its previous decision and now recommends approval for Biogen's Leqembi, an Alzheimer's drug, in Europe.
• The approval is limited to specific patient populations based on genetic markers, potentially impacting around 30% of the drug's global sales.
• Despite the positive EMA decision, Biogen faces challenges including pricing, reimbursement, logistical issues, and the need to expand its product pipeline.
• Leqembi demonstrated significant slowing of cognitive decline in specific patient groups, supporting potential for increased market adoption and revenue generation.
UCB and Biogen's Dapirolizumab Pegol Shows Promise in Phase 3 Lupus Trial
• UCB and Biogen's dapirolizumab pegol met the primary endpoint in a Phase 3 trial for moderate-to-severe systemic lupus erythematosus (SLE).
• The drug demonstrated significant clinical improvement in disease activity compared to placebo when added to standard of care.
• A second Phase 3 trial, PHOENYCS FLY, is planned to further evaluate the efficacy and safety of dapirolizumab pegol in SLE patients.
• Dapirolizumab pegol targets the CD40L pathway, offering a novel approach to reduce B cell activation and autoantibody production in SLE.
FDA Approves Genentech's Ocrevus Zunovo as First Twice-Yearly Subcutaneous MS Treatment
• The FDA has approved Ocrevus Zunovo, a subcutaneous injection, for relapsing and primary progressive multiple sclerosis.
• Ocrevus Zunovo is the first and only twice-a-year, 10-minute subcutaneous treatment option for both forms of MS.
• Approval was based on the Phase III OCARINA II trial, demonstrating similar efficacy and safety to the IV formulation of Ocrevus.
• The new formulation offers greater flexibility for healthcare providers and patients, especially those with IV access constraints.
FDA Approves Roche's Injectable Ocrevus for Multiple Sclerosis
• The FDA has approved Roche's subcutaneous injectable version of Ocrevus for treating multiple sclerosis, offering a quicker 7-minute administration time.
• The approval was based on the OCARINA II trial, demonstrating non-inferiority to the intravenous formulation regarding drug levels and similar safety profiles.
• The injectable Ocrevus, to be available starting in October, expands treatment access by allowing administration in neurologist offices, avoiding specialized infusion centers.
• Ocrevus targets CD20-positive B cells, key contributors to nerve cell damage, and has treated over 350,000 MS patients globally with the IV formulation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath